Many peptides are unlikely to ever receive FDA approval because their simple, easily replicated structures make them commodities. Pharma companies won't fund billion-dollar trials for drugs they can't patent, leaving them in a permanent gray market.

Martin Shkreli claims that from a pharmaceutical development perspective, peptides are often avoided. They possess inherent weaknesses, being more complex than small molecules but less effective than large molecules like antibodies. This makes their recent popularity in biohacking circles ironic to industry insiders.

While GLP-1 has been a known target for a long time, the recent explosion in peptide therapeutics was primarily enabled by solving the historical challenge of poor half-life and exposure. Achieving one- or two-week half-lives through techniques like fatty acid acylation was the critical technological unlock for the field.

The critique of the peptide trend often misses that users aren't taking unknown chemicals. Many use compounds like Retatrutide, which is already in Phase 3 clinical trials by Eli Lilly. They are essentially front-running the FDA approval process for drugs that already have substantial clinical backing.

The FDA defines a peptide as an amino acid chain of 40 or less. Blockbuster drugs like Ozempic and Mounjaro are all exactly 39 amino acids long. This perfect fit suggests potential regulatory shaping or clever drug design to fit an advantageous classification.

Martin Shkreli dismisses the biohacking trend of using peptides. He argues that without rigorous data on pharmacokinetics—how a substance is metabolized and its half-life—one doesn't have a medicine, but a delusion. He criticizes enthusiasts for ignoring the foundational science required for any pharmaceutical.

Andrew Huberman suggests that an impending crackdown on gray market peptides is motivated by pharmaceutical giant Eli Lilly's desire to protect its patent on Retatrutide, a potential trillion-dollar weight-loss drug. The push for regulation may be less about public safety and more about eliminating low-cost, gray-market alternatives to a blockbuster product.

Martin Shkreli argues the pharmaceutical industry avoids peptides due to inherent weaknesses like short half-lives, viewing them as the 'worst of both worlds' compared to small molecules or antibodies. This perspective reframes the peptide craze as an elevation of a scientifically challenging and often impractical drug class.

Shkreli dismisses the peptide trend popular in tech circles. He contends that without understanding a drug's half-life (pharmacokinetics), its specific biological target, and rigorous double-blind trial data, users are engaging in delusion, not science. He criticizes the dismissal of the FDA and established pharma processes.